CARL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Carlsmed Inc (CARL) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has shown strong revenue and net income growth in its latest quarter, the lack of significant positive trading signals, neutral insider and hedge fund activity, and limited near-term upside potential suggest holding off on investment for now. The stock's technical indicators are neutral, and there are no significant catalysts or news to drive immediate growth.
The MACD is positive and expanding, indicating a potential upward trend. However, the RSI is neutral at 62.643, and moving averages are converging, suggesting no clear momentum. The stock is trading near its resistance level (R1: 10.81), which may limit immediate upside potential.
Strong revenue growth (+61.19% YoY) and improved gross margin (76.54%, up 2.52% YoY) in the latest quarter. Analysts maintain a Buy rating despite lowering price targets, citing the company's faster top-line growth and higher gross margin profile.
No recent news or significant trading trends. Analysts have lowered price targets, reflecting cautious sentiment. Stock trend analysis suggests limited short-term upside, with a potential -9.55% decline in the next month.
In Q4 2025, revenue increased by 61.19% YoY to $15.165 million. Net income improved by 82.48% YoY but remains negative at -$8.613 million. EPS improved by 77.78% YoY to -0.32. Gross margin increased to 76.54%, up 2.52% YoY.
Analysts maintain a Buy rating but have lowered price targets recently (Truist: $18 from $20, BTIG: $23 from $24). Analysts cite strong top-line growth and gross margin as positives but acknowledge cautious sentiment around Q1 volumes and regulatory updates.
